Skip to content
DataLookout
Menu

TRICARNCT05064514

Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from May 21, 2026 to May 21, 2028
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: details revised at 2 of 7 entries
  2. Minor Primary completion date: Oct 2026 to May 21, 2026
    • Study completion date: Mar 2028 to May 21, 2028
    v8
  3. Notable Primary completion date: Oct 2025 to Oct 2026v7
  4. Notable Primary completion date: Oct 2023 to Oct 2025
    • Study completion date: Mar 2026 to Mar 2028
    v6
  5. Minor Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Oct 2022 to Apr 6, 2022
    • Site contact updated
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Start date: Jun 6, 2022 to Oct 2022
    • Primary completion date: Jun 2023 to Oct 2023
    • Study completion date: Oct 2025 to Mar 2026
    v4
  2. Notable Start date: Mar 2022 to Jun 6, 2022
    • Primary completion date: Mar 2023 to Jun 2023
    • Study completion date: Aug 2025 to Oct 2025
    v3
  3. Notable Start date: Sep 2021 to Mar 2022v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The number of patients with successful implantation of the TRICENTO bioprosthesis
Timeframe: measured pre intervention and immediately after the intervention

Secondary (7)

To assess the safety of the Tricuspid Valved Stent Graft implantation procedure in patients with carcinoid heart disease with severe symptomatic TR and significant systolic backflow in the hepatic and caval veins, and who are not suitable for surgery.
•To evaluate the reduced symptom burden according to New York Heart Association (NYHA) score
To evaluate the change in peripheral oedema experienced by patients
To evaluate the change in of number of admissions to hospital for heart failure
To evaluate the change in patient reported quality of life (EuroQol- 5 Dimension - EQ5D)
Show 2 moreShow less
To evaluate the change in patient reported quality of life (Kansas City Cardiomyopathy Questionnaire (KCCQ))
To evaluate the change in patient reported quality of life (Minnesota Living With Heart Failure - MLFHQ)

Arms and interventions

Transcatheter Tricuspid Valved Stent Graft interventionExperimental

Participants who have carcinoid heart disease with severe symptomatic tricuspid regurgitation and with a significant backflow in the caval and hepatic veins will be treated with the implantation of the Transcatheter Tricuspid Valved Stent Graft

Devices: Transcatheter Tricuspid Valved Stent Graft

Sites

1 site in 1 country

  • Barts Health NHS TrustLondon, England, United Kingdom